Green Cross Corporation
006280 | KO
Overview
Corporate Details
- ISIN(s):
- KR7006280002
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 이현로30번길 107(보정동), 용인시
- Website:
- https://www.gccorp.com/eng/index
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-22 00:00 |
Regulatory Filings
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 13.2 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 4.2 MB | ||
| 2025-08-05 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 25.5 KB | ||
| 2025-08-01 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.0 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 4.2 MB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 3.2 MB | ||
| 2025-04-30 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.0 KB | ||
| 2025-04-08 00:00 |
Regulatory Filings
투자판단관련주요경영사항
|
Korean | 8.5 KB | ||
| 2025-04-08 00:00 |
Management Reports
[기재정정]장래사업ㆍ경영계획(공정공시)
|
Korean | 14.0 KB | ||
| 2025-03-31 00:00 |
Management Reports
[기재정정]장래사업ㆍ경영계획(공정공시)
|
Korean | 11.7 KB | ||
| 2025-03-27 00:00 |
Major Shareholding Notification
최대주주등소유주식변동신고서
|
Korean | 50.2 KB | ||
| 2025-03-26 00:00 |
AGM Information
정기주주총회결과
|
Korean | 19.8 KB | ||
| 2025-03-18 00:00 |
Audit Report / Information
사업보고서 (2024.12)
|
Korean | 717.7 KB | ||
| 2025-03-18 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 19.6 KB | ||
| 2025-03-13 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.8 KB |
Automate Your Workflow. Get a real-time feed of all Green Cross Corporation filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Green Cross Corporation
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Green Cross Corporation via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX
United States of America
MGNX
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
United States of America
MDGL
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Sweden
MAGLE
Developing telomere-targeting immuno-oncology therapies for difficult-to-treat cancers.
United States of America
MAIA
United States of America
MAIA
Germany
MYNZ
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
United States of America
MNKD
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
United States of America
MRVI
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Austria
MARI
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
United States of America
MRKR
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE
United States of America
MAZE